NCT06778967View on ClinicalTrials.gov

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

August 28, 2026

Study Completion Date

December 11, 2026

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

GZR18

Administered SC

DRUG

semaglutide

Administered SC

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY